NCT00311545撤回2 期
A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), In Patients With Advanced or Metastatic Renal Cell Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
研究概览
简要总结
RATIONALE: Monoclonal antibodies, such as CNTO 328, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
PURPOSE: This phase II trial is studying how well CNTO 328 works in treating patients with unresectable or metastatic kidney cancer.
详细描述
OBJECTIVES:
Primary
- Assess the probability of response (confirmed complete and partial responses) in patients with unresectable or metastatic renal cell cancer treated with CNTO 328.
Secondary
- Assess the 6-month progression-free survival probability and median overall survival in these patients.
- Evaluate the qualitative and quantitative toxicities of this treatment.
- Investigate, in a preliminary manner, the association of tumor response with potential markers of anti-interleukin-6 activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
2 期
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyProstate CancerNCT00433446SWOG Cancer Research Network62
终止
2 期
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube CancerFallopian Tube CancerPeritoneal Cavity CancerOvarian CancerNCT01137071Recepta Biopharma29
已完成
2 期
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by SurgeryPancreatic CancerNCT00601627Alliance for Clinical Trials in Oncology52
终止
2 期
Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By SurgeryBreast CancerNCT00674414UNICANCER82
已完成
2 期
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal CancerColorectal CancerNCT00556413Institut du Cancer de Montpellier - Val d'Aurelle42